Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “
Company”
or “
Relevium”), is pleased to
announce that its OTC business has launched a new line of omega
fish oils based formulations targeting inflammation, heart and
vision care.
High End Omega Based Product
Line
The Company has launched an initial two omega
formulated products to support heart health and vision care:
CardiaProtm and VisionProtm, leading the way to a complete line of
scientifically formulated products targeting inflammation.
Inflammation, which is a process by which the
body's natural immune response seeks to protect us from infection
with foreign organisms, such as bacteria and viruses. However, as a
result of our environment and modern lifestyles, our immune
response remains on a constant “state of alarm” leading to a
constant state of immune response leading to inflammation and
causing chronic conditions of pain, inflammation and dysfunction.
Our new line of health products leverages the inflammation fighting
benefits of the omega spectrum of fatty acids through exclusive
targeted formulations to support specific health functions such as
heart, vision and joints.
Subject to the positive adoption of cannabidiol
as a health supplement by the FDA and complete clearance of the
legal context in the US, the company’s OTC business plans to
leverage the anti-inflammatory and pain reduction benefits of this
cannabinoid, which is the center of much expectation from the
Health and Wellbeing market.
Abis Hussain, CMO, stated: “We have started the
process of shifting towards scientific based formulations,
targeting niche and focused product offerings in high demand, such
as is the case of inflammation,” Mr. Hussain stated further “Our
Heart and Vision formulations will be sold primarily through social
media and through some of our major market places. However, we are
also pursuing a brick and click strategy thus extending our
offering through health stores.”
Update on Push and Pulltm Anti-Aging
System
Launched earlier this year, the Company’s Push
and Pull Anti-Aging System, targeting the Hispanic market in North
America, has been successfully deployed in the Puerto Rican market
and the company plans to expand its target to South Florida, Texas,
California and Mexico.
The company’s Direct Response Campaigns have
been tested in several consumer segments and subject to its
successful deployment in these Hispanic markets, it plans to open
the product offering to other focused demographics in the US.
Aurelio Useche, CEO Stated: “Our entry into the
highly competitive Anti-Ageing Market was a bold move by our team,
which is why we focused on specific demographics and to understand
their specific needs and shopping habits. The North American
anti-aging market is estimated to be an $18 Billion business with a
steady 5.2% CAGR growth, and our target is to play a niche role in
the space.”
About Relevium Technologies
Relevium is a publicly-traded company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operations of brands and businesses in
the Health and Wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products.
Relevium operates through two wholly-owned
subsidiaries:
BGX E-Health LLC (BGX): Based
in Orlando, Florida, BGX is our OTC business that markets dietary
supplements, nutraceuticals, sports nutrition and cosmeceuticals
primarily through its Bioganix® brand portfolio in the US and
Europe. Relevium’s brands such as Bioganix® are sold at
some of the world’s largest retailers including such as Walmart.com
and Amazon.com.
Biocannabix Health Corporation
(BCX): Based in Montreal, Quebec, BCX is an
entrepreneurial venture to establish an integrated medical cannabis
company in the Nutraceutical space targeting pediatric support in
conjunction with traditional medical therapies.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions or expectations of future
performance, including the timing and completion of the proposed
acquisitions, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", "would" or "occur".
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including the assumptions that the Company will be able to apply
for and ultimately obtain an ACMPR licence, the proposed business
of Biocannabix will develop as anticipated, that the Company will
raise sufficient funds to develop the Biocannabix business, and
that the Company will obtain all requisite regulatory approvals.
These forward-looking statements are subject to known and unknown
risks, uncertainties and other factors that may cause the actual
results, level of activity, performance or achievements of the
Company to be materially different from those expressed or implied
by such forward-looking statements or forward-looking information.
Important factors that may cause actual results to vary, include,
without limitation, the risk that the proposed business
developments may not occur as planned; the timing and receipt of
requisite approvals and failure to raise sufficient funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.comWebsite: www.releviumtechnologies.com
Like us on Facebook Follow us on TwitterFollow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024